Bcr-abl t(9;22) Translocation Assay

These data were generated using our proprietary Bcr-abl RT-PCR Assay (Cat#103-24). The green peak at 94 bp is the abl cDNA control; the other green peaks represent e1-a2 and e1-a3 products. The blue peaks represent b2 exon-specific products. The black peak is b3 exon-specific. UPPER PANEL: Normal cDNA control sample. Evident is the 94 basepair abl transcript amplicon control. MIDDLE PANEL: Positive t(9;22) bcr-abl sample with b2a2 junction. BOTTOM PANEL: Positive t(9;22) bcr-abl sample with a b3a2 junction. The blue peaks at 126 bp and 311 bp represent b2a2 and b2a3 specific amplicon products, respectively. The black peak at 242 bp represents a b3a3 amplicon product.

Product Description:

This RT-PCR bcr-abl assay identifies Bcr-abl t(9;22) chromosomal translocations that are a hallmark of chronic myeloid leukemia (CML) and result in the characteristic cytogenetic abnormality termed the Philadelphia chromosome (Nowell, PC. 1960. Science 132:1497 and Rowley, JD. 1973. Nature 243:290). These translocations are associated to a lesser extent with acute lymphoblastic leukemia (ALL) and other hematologic malignancies. This assay targets the Abl transcript as the control for RNA and cDNA adequacy. The kit contains protocols, 1st round and 2nd round master mixes, and RNA controls for complete analysis of 28 samples. Patent Pending.

IVS Technologies, L.L.C., 2915 Avenida Valera, Carlsbad, CA 92009. Tel: 877-431-6705; Fax: 760-431-6909.